The world's first innovative drug for the treatment of PIK3CA mutant breast cancer, Alpelisib, is introduced to Boao

Recently, Novartis's drug Piqray® (Alpelisib) for the treatment of advanced breast cancer was prescribed in Hainan Boao Super Hospital, and domestic patients can benefit from innovative drugs simultaneously globally

Breast cancer with PIK3CA mutation presents treatment challenges

According to the latest global cancer data for 2020 released by the International Agency for Research on Cancer (IARC) of the World Health Organization, there are 2.

Data from Chinese studies show that 49.

For more than ten years, domestic and foreign has been committed to the development of drugs for the PI3K signaling pathway, but most of them are concentrated in hematological tumors and lymphomas

The launch of Novartis' innovative drug Alpelisib is critical to change the treatment pattern of HR+/HER2- advanced breast cancer patients with PIK3CA mutations, and it also provides clinicians and patients with a clear treatment method

Alpelisib brings hope to breast cancer patients with PIK3CA mutations

Alpelisib is the first drug for advanced breast cancer with HR+/HER2- and PIK3CA mutations.

Professor Ma Fei, director of the Medical Treatment Center of the Cancer Hospital of the Chinese Academy of Medical Sciences , said: "The results of the SOLAR-1 study prove that the combination of Alpelisib and fulvestrant can prolong the progression-free survival of patients with PIK3CA mutations

Dr.

With innovation as the cornerstone, Novartis has long been committed to the research and development of innovative drugs with the potential to transform standard treatments

Novartis Oncology (China) General Manager Ji Bicheng said, "I am very happy that Alpelisib can land in Boao and bring new treatment options to Chinese breast cancer patients

References:

1 "2020 Latest Global Cancer Data Report"

2 Jia M, Liao N, et al.

5 André F, et al.